VECTIVBIO HOLDING AG VectivBio Holding AG announced the appointment of Patrick Malloy as Senior Vice President, Investor Relations and Strategic Communications. Mr. Malloy's two decades of investor relations and commercial leadership experience strengthens VectivBio as it continues to evolve into a fully integrated, rare disease leader. Mr. Malloy joins VectivBio after more than four years at Arena Pharmaceuticals, recently acquired by Pfizer, where he served as Vice President of Investor Relations and Corporate Communications.
Prior joining Arena, Mr. Malloy spent over 16 years at Actelion Pharmaceuticals (acquired by Johnson and Johnson in June 2017) where he held several commercial and corporate strategic leadership roles across the organization. Mr. Malloy will be based in the United States and provides VectivBio more immediate access to key investors.
